Cargando…

A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes

BACKGROUND: In the MADIAB trial (a 21-day randomized, controlled trial in patients with type 2 diabetes (T2D)), intervention with the Ma-Pi 2 macrobiotic diet resulted in significantly greater improvements in metabolic control compared with a standard recommended diet for patients with T2D. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Soare, A, Del Toro, R, Khazrai, Y M, Di Mauro, A, Fallucca, S, Angeletti, S, Skrami, E, Gesuita, R, Tuccinardi, D, Manfrini, S, Fallucca, F, Pianesi, M, Pozzilli, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022142/
https://www.ncbi.nlm.nih.gov/pubmed/27525817
http://dx.doi.org/10.1038/nutd.2016.29
_version_ 1782453463772299264
author Soare, A
Del Toro, R
Khazrai, Y M
Di Mauro, A
Fallucca, S
Angeletti, S
Skrami, E
Gesuita, R
Tuccinardi, D
Manfrini, S
Fallucca, F
Pianesi, M
Pozzilli, P
author_facet Soare, A
Del Toro, R
Khazrai, Y M
Di Mauro, A
Fallucca, S
Angeletti, S
Skrami, E
Gesuita, R
Tuccinardi, D
Manfrini, S
Fallucca, F
Pianesi, M
Pozzilli, P
author_sort Soare, A
collection PubMed
description BACKGROUND: In the MADIAB trial (a 21-day randomized, controlled trial in patients with type 2 diabetes (T2D)), intervention with the Ma-Pi 2 macrobiotic diet resulted in significantly greater improvements in metabolic control compared with a standard recommended diet for patients with T2D. We report on a 6-month follow-up study, which investigated, whether these benefits extended beyond the 21-day intensive dietary intervention, in real-world conditions. SUBJECTS: At the end of the MADIAB trial (baseline of this follow-up study), all participants continued their assigned diet (Ma-Pi or control) for 6 months. The Ma-Pi 2 group followed the Ma-Pi 4 diet during this follow-up study. Forty of the original 51 subjects (78.4%) participated in the follow-up (body mass index, 27–45 kg m(−2); age, 40–75 years). Primary outcome was percentage change from baseline in HbA1c; secondary outcomes were anthropometric data and lipid panel. RESULTS: A significantly greater median percentage reduction was observed for HbA1c in the Ma-Pi group (−11.27% (95% confidence interval (CI): −10.17; −12.36)) compared with the control group (−5.88% (95% CI: −3.79; −7.98)) (P < 0.001). Total and low-density lipoprotein (LDL) cholesterol increased in both groups with no differences between groups (P=0.331 and P=0.082, respectively). After correcting for age and gender, the Ma-Pi diet was associated with a higher percentage reduction in HbA1c (95% CI: 2.56; 7.61) and body weight (95% CI: 0.40; 3.99), and a higher percentage increase in LDL cholesterol (95% CI: −1.52; −33.16). However, all participants' total and LDL cholesterol levels remained within recommended ranges (<200 mg dl(−1) and <100 mg dl(−1), respectively). The Ma-Pi diet group achieved the target median HbA1c value (<5.7% (39 mmol mol(−1))) at 6 months. CONCLUSIONS: Both the Ma-Pi and control diets maintained their benefits beyond the 21-day intensive monitored intervention over a 6-month follow-up in real-world conditions. The Ma-Pi diet resulted in greater improvement in glycemic control.
format Online
Article
Text
id pubmed-5022142
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50221422016-09-20 A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes Soare, A Del Toro, R Khazrai, Y M Di Mauro, A Fallucca, S Angeletti, S Skrami, E Gesuita, R Tuccinardi, D Manfrini, S Fallucca, F Pianesi, M Pozzilli, P Nutr Diabetes Original Article BACKGROUND: In the MADIAB trial (a 21-day randomized, controlled trial in patients with type 2 diabetes (T2D)), intervention with the Ma-Pi 2 macrobiotic diet resulted in significantly greater improvements in metabolic control compared with a standard recommended diet for patients with T2D. We report on a 6-month follow-up study, which investigated, whether these benefits extended beyond the 21-day intensive dietary intervention, in real-world conditions. SUBJECTS: At the end of the MADIAB trial (baseline of this follow-up study), all participants continued their assigned diet (Ma-Pi or control) for 6 months. The Ma-Pi 2 group followed the Ma-Pi 4 diet during this follow-up study. Forty of the original 51 subjects (78.4%) participated in the follow-up (body mass index, 27–45 kg m(−2); age, 40–75 years). Primary outcome was percentage change from baseline in HbA1c; secondary outcomes were anthropometric data and lipid panel. RESULTS: A significantly greater median percentage reduction was observed for HbA1c in the Ma-Pi group (−11.27% (95% confidence interval (CI): −10.17; −12.36)) compared with the control group (−5.88% (95% CI: −3.79; −7.98)) (P < 0.001). Total and low-density lipoprotein (LDL) cholesterol increased in both groups with no differences between groups (P=0.331 and P=0.082, respectively). After correcting for age and gender, the Ma-Pi diet was associated with a higher percentage reduction in HbA1c (95% CI: 2.56; 7.61) and body weight (95% CI: 0.40; 3.99), and a higher percentage increase in LDL cholesterol (95% CI: −1.52; −33.16). However, all participants' total and LDL cholesterol levels remained within recommended ranges (<200 mg dl(−1) and <100 mg dl(−1), respectively). The Ma-Pi diet group achieved the target median HbA1c value (<5.7% (39 mmol mol(−1))) at 6 months. CONCLUSIONS: Both the Ma-Pi and control diets maintained their benefits beyond the 21-day intensive monitored intervention over a 6-month follow-up in real-world conditions. The Ma-Pi diet resulted in greater improvement in glycemic control. Nature Publishing Group 2016-08 2016-08-15 /pmc/articles/PMC5022142/ /pubmed/27525817 http://dx.doi.org/10.1038/nutd.2016.29 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Soare, A
Del Toro, R
Khazrai, Y M
Di Mauro, A
Fallucca, S
Angeletti, S
Skrami, E
Gesuita, R
Tuccinardi, D
Manfrini, S
Fallucca, F
Pianesi, M
Pozzilli, P
A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes
title A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes
title_full A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes
title_fullStr A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes
title_full_unstemmed A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes
title_short A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes
title_sort 6-month follow-up study of the randomized controlled ma-pi macrobiotic dietary intervention (madiab trial) in type 2 diabetes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022142/
https://www.ncbi.nlm.nih.gov/pubmed/27525817
http://dx.doi.org/10.1038/nutd.2016.29
work_keys_str_mv AT soarea a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT deltoror a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT khazraiym a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT dimauroa a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT falluccas a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT angelettis a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT skramie a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT gesuitar a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT tuccinardid a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT manfrinis a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT falluccaf a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT pianesim a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT pozzillip a6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT soarea 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT deltoror 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT khazraiym 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT dimauroa 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT falluccas 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT angelettis 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT skramie 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT gesuitar 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT tuccinardid 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT manfrinis 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT falluccaf 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT pianesim 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes
AT pozzillip 6monthfollowupstudyoftherandomizedcontrolledmapimacrobioticdietaryinterventionmadiabtrialintype2diabetes